Goodman 2009

1 Treatments

**Studied treatment**  
ildagliptin 100 mg given in the morning, vildagliptin 100 mg given in the evening

**Control treatment**  
placebo

**Concomittant treatments**  
metformin

2 Patients

**Patients**  
patients inadequately controlled with metformin

**Inclusion criteria**  
-

**Exclusion criteria**  
-

3 Methods

**Blinding**  
double-blind

**Design**  
Parallel groups

**Centers**  
-

**Geographical area**  
-

**Sizes**  
125/122

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>stroke</td>
<td>-/125</td>
<td>-/122</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>HbA1c goal &lt;7 all cause deaths</td>
<td>-/125</td>
<td>-/122</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>nephropathy</td>
<td>-/125</td>
<td>-/122</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV events</td>
<td>-/125</td>
<td>-/122</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV deaths</td>
<td>-/125</td>
<td>-/122</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>MI</td>
<td>-/125</td>
<td>-/122</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all hypoglycemia</td>
<td>1/125</td>
<td>0/122</td>
<td>2.93</td>
<td>[0.12; 72.59]</td>
</tr>
<tr>
<td>Adverse events leading to treatment discontinuation</td>
<td>-/125</td>
<td>-/122</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References